Prime Medicine is using the latest CRISPR technology to bring gene editing to patients. Prime editing is an innovative new approach to achieve precision genome editing without inducing double-stranded breaks. This enables safer and more efficient editing and has the potential to address more than 90% of known disease-causing mutations. Prime Medicine is using this “search and replace” tool to restore normal genetic function to almost anywhere in the genome. To develop their pipeline, Prime is working with Beam Therapeutics to enhance therapeutic delivery and manufacturing. 

<p>Prime Medicine is using the latest CRISPR technology to bring gene editing to patients. Prime editing is an innovative new approach to achieve precision genome editing without inducing double-stranded breaks. This enables safer and more efficient editing and has the potential to address more than 90% of known disease-causing mutations. Prime Medicine is using this “search and replace” tool to restore normal genetic function to almost anywhere in the genome. To develop their pipeline, Prime is working with Beam Therapeutics to enhance therapeutic delivery and manufacturing. </p>


Prime Medicine

Contractor, Lab Operations Technician

Director of Safety Assessment

Contractor, GMP Technician

Senior Clinical Trial Manager

Contractor, Patient Advocacy and Medical Affairs

Patent Agent 

Prime Medicine stock plummets amid restructuring and leadership changes - Investing.com

 Prime Medicine GAAP EPS of -$0.44 beats by $0.03, revenue of $0.59M misses by $0.32M 

Prime Medicine refocuses on liver disease, leadership changes - Investing.com

It was another successful Halloween at Prime! We held our annual costume contest along with a candy bar and pumpkin decorating event. We had polar seltzers, a heavy metal rock band, a wizard, among others, in our office for the day. Check it out!

Chardan cuts Prime Medicine stock target to $12, maintains Buy - Investing.com

 Prime Medicine upgraded at Citi on valuation, pipeline 


						3_18_25
						Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
					

Prime Medicine Executives Make Significant Stock Purchases - TradingView

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences

 Prime Medicine 19.2M share Spot Secondary priced at $6.25 

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher - Benzinga

Revolutionary Gene Editing Breakthrough: Prime Medicine's AATD Treatment Shows 95% Protein Restoration - Stock Titan

First Human Prime Editing Trial Shows 66% Success in Rare Disease Treatment | PRME Stock News - Stock Titan

 Prime Medicine announces new α1-antitrypsin deficiency program 


												10_19_19
												nature												Search-and-replace genome editing without double-strand breaks or donor DNA
												Andrew V. Anzalone, Peyton B. Randolph, Jessie R. Davis, Alexander A. Sousa, Luke W. Koblan, Jonathan M. Levy, Peter J. Chen, Christopher Wilson, Gregory A. Newby, Aditya Raguram & David R. Liu											

The biotech news you need to read today - STAT

Prime Medicine Secures $55 Million Deal with Bristol Myers Squibb to Develop Next-Gen T-Cell Therapies - SynBioBeta

 Bristol, Prime Medicine in deal to develop T-cell therapies 

Prime Medicine Reports Q1 2025 Financial Results - TipRanks

Prime Medicine, Inc.: Buy Rating Backed by Promising Gene Editing Advancements and Robust Pipeline - TipRanks

Prime Medicine’s Promising Clinical Data and Favorable Market Conditions Make It a Buy - TipRanks

Jefferies cuts Prime Medicine stock target to $9, maintains Buy - Investing.com

Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks

Prime Medicine shares rise on $3.5 billion BMS collaboration - Investing.com


						2_28_25
						Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
					

Prime Medicine soars as it inks research collab with BMS - The Pharma Letter

 ASGCT24: Prime Medicine to Apply Gene Editing to Wide-Ranging Indications 

 FDA Clears Prime Medicine's IND for First Prime Editing Therapy 

Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com Nigeria


						5_8_25
						Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
					

Prime to narrow gene editing research as it strikes deal with Bristol Myers - BioPharma Dive

BMS and Prime ink potential $3.5bn deal to develop T cell therapies - Yahoo Finance

Prime Medicine stock plummets amid restructuring and leadership changes - MSN

We're headed to San Diego this week for #ASH24, where Associate Director Jack Heath will share research demonstrating that Prime Editing can potentially be used to develop shielded HSCs that can be used in combination with antibody-based conditions regimens, eliminating the need for toxic chemotherapy regimens prior to transplantation. Read the full abstract here. https://lnkd.in/ejjhGAsg

 Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics 

Prime CTO Ann Lee will join Georgia Tech Research at their upcoming Immunoengineering Industry Symposium to give a keynote presentation on Prime Editing. Learn more about Friday's event here. https://lnkd.in/e5Xh-MtC

Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

 The Top 7 Biopharma Licensing Deals of 2024 

Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity - TipRanks

Prime Medicine initiated with an Outperform at JMP Securities - MSN

Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits - Genetic Engineering and Biotechnology News

ASGCT24: Prime Medicine to Apply Gene Editing to Wide-Ranging Indications - BioSpace

PRME Stock Rises 11.8% on Collaboration With Bristol Myers - Yahoo Finance

Prime Medicine gets green light for trials of first-ever prime editing drug - Clinical Trials Arena


												1_8_24
												Nature Biotechnology												Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo
												Meirui An, Aditya Raguram, Samuel W. Du, Samagya Banskota, Jessie R. Davis, Gregory A. Newby, Paul Z. Chen, Krzysztof Palczewski & David R. Liu											

 Broad, Harvard researchers win Breakthrough Prize, known as 'Oscars of Science' 

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? - Yahoo Finance

At a time when biotech business trends are uncertain and many patients are still waiting on new treatments, many may ask, where does #CRISPR go from here? Prime CEO Keith Gottesdiener looks forward to addressing this during the Endpoints News Catalysts event alongside other industry leaders this month. Register for the free, virtual event here. https://lnkd.in/g--qQNPg

Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks

Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 - Seeking Alpha


												8_31_23
												Cell												Phage-assisted evolution and protein engineering yield compact, efficient prime editors
												Jordan L. Doman, Smriti Pandey, Monica E. Neugebauer, Meirui An, Jessie R. Davis, Peyton B. Randolph, Amber McElroy, Xin D. Gao, Aditya Raguram, Michelle F. Richter, Kelcee A. Everette, Samagya Banskota, Kathryn Tian, Y Allen Tao, Jakub Tolar, Mark J. Osborn & David R. Liu											

Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks

Prime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.com - MarketBeat

JPMorgan cuts Prime Medicine stock rating to neutral - Investing.com

 Prime Medicine initiated with bullish view at JMP Securities, here's why 

PRIME: priority medicines - European Medicines Agency |


						5_19_25
						Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
					

 Why Prime Medicine Stock Was Climbing Higher This Week 

 With 34% ownership, Prime Medicine, Inc. (NASDAQ:PRME) has piqued the interest of institutional investors 

Co-founder and Head of Prime Editing Platform Andrew Anzalone joined other industry leaders at the Genome Editing Therapeutics Summit in Boston this week! Learn more about his presentation below. 


						11_12_24
						Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
					

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

New prime editor delivery particles help restore vision in mice

 Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics 

 Pharmas Turn to Licensing Deals as Risky Science Rises 

 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates 


						5_19_25
						Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
					

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Prime Medicine uncloaks with $315M to push 'search and ...

Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO - geneonline.com

Why Prime Medicine Stock Is Soaring Today - The Motley Fool

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday - The Motley Fool

When the FDA requires a large vaccine trial, who pays? - STAT

Prime Medicine Faces Downgrades, Significant Price Slash by Citigroup - timothysykes.com

 Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley 

Prime and Beam, born of same lab, pursuing rival gene-editing treatments - statnews.com

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

A radiopharmaceuticals startup raises $175 million - STAT

Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus

Prime gets FDA green light to begin first trial test of ‘prime editing’ - BioPharma Dive

 Form 424B5 Prime Medicine, Inc. 

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Yahoo Finance

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb - MarketWatch

Wilson Sonsini Advises Prime Medicine on IP Matters Related to Upsized Public Offering - Wilson Sonsini

PRME SEC Filings - Prime Medicine 10-K, 10-Q, 8-K Forms - Stock Titan

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga

Prime Medicine Reports Q3 2024 Financial Progress - TipRanks

 Is prime editing ready for prime time? 

Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating - TipRanks

Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb - STAT

Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com

Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks

Prime Medicine Prioritizes Pipeline, Cuts Workforce By 25% - Stock Plunges - Nasdaq

Prime Medicine

Business:

About: